companies / retro-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 1,180,000,0001.2B | ○ |
|---|---|---|
| founded | 2021 | |
| hq | San Francisco, US | |
| industry | unknown | |
| stage | series-a |
Retro Biosciences develops therapeutics that extend healthy lifespan, with programs in autophagy, cellular reprogramming, and plasma fractions. The audience is patients with age-driven diseases and clinicians seeking interventions that target biological aging. Retro is funded in large part by Sam Altman's personal capital.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-24 | series-a | 1,000,000,0001.0B | null | ○ |
Vercel, Next.js, React
| fact | status | src |
|---|---|---|
| Series A, $1.0B | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |